Efficacy of α-lipoic acid in compensation of the contractive function disorders of the skeletal muscle caused by long-term dexamethazone treatment in animal experiments
Abstract
The aim of the study was to evaluate the efficacy of a-lipoic acid (a-LA) in correcting disorders of the contractile function of a mixed type skeletal muscle (m. tibial anterior) induced by chronic dexamethasone (DM) treatment in an animal model.
Methods. Experiments were performed on sexually mature female rats (190-200 g) divided into four groups: control (intact rats, C group, n=10), experimental group 1 (30-day dexamethasone treatment, DM group, n=10), experimental group 2 (30-day dexamethasone plus a-lipoic acid treatment, DM+a-LA group, n=10), and experimental group 3 (30-day a-lipoic acid treatment, a-LA group, n=10). Dexamethasone (KRKA, Slovenia) was administered every two days, i.p., at a dose of 0.25 mg/kg, which was equivalent to the clinical therapeutic dose. a-Lipoic acid (Berlition-600, BERLIN-CHEMIE, Germany) was administered daily at a dose of 35 mg/kg, s.c. Stimulation electromyography and myography were performed in an acute experiment, under sodium thiopental (100 mg/kg) anesthesia, on day 30. Electrophysiological and contractile parameters of the anterior tibial muscle were recorded during stimulation with suprathreshold electrical current via the fibular nerve.
Results. a-LA in combination with DM prevented decreases in the number of activated muscular motor units (MMU) and muscle mass, the degree of the muscle post-tetanic potentiation, and disorders of contractile and temporal parameters of single and tetanic contractions, which were typical for animals of the DM group. The a-LA plus DM treatment even significantly increased the relaxation rate of a single contraction (by 34%) and the rate of tetanic contraction development (by 80%) compared to the control group (p<0.05), which were also typical for the a-LA group. These facts indirectly evidence the absence of pronounced dystrophic changes in muscle fibers in animals of the DM+a-LA group. At the same time, although the shortened period of maximum muscle work capacity, which was typical for the DM group, was not observed in the DM+a-LA group, this period was no longer than in the control either, as distinct from the a-LA group. This fact suggests the absence of positive effects of a-LA on the muscle work capacity when a-LA is administered in combination with DM. The a-LA+DM treatment reversed the increased fatigue and the reduced ability to recover of the muscle after fatigable work (FW) observed in the DM group. Moreover, the a-LA+DM treatment even increased the rate of muscle recovery after FW, which was also characteristic for the a-LA group. This was confirmed by the absence of decreased rates of muscle shortening after FW, which was typical for the DM group, and by the absence of significant decreases in the single contraction amplitude and the number of activated MMU after FW, which was typical not only for the DM group, but also for the control.
Conclusion. The changes in muscle functional parameters in the DM and DM+a-LA groups evidence pronounced contractile disorders and impaired ability of the muscle to recover after FW in the DM group. In the DM+a-LA group, the muscle contractile function was not significantly impaired. Moreover, the muscle ability to recover after FW was not reduced in the DM+a-LA-group. In this group, the ability to recover was even increased compared to the control, which was also characteristic for the a-LA-group. These facts allow considering a-LA as a possible therapy for correction of steroid myopathy.
Downloads
References
2. Gardner D., Shoback D. Greenspan's Basic and Clinical Endocrinology. 9th ed. New York: McGraw-Hill Medical; 2011.
3. Polunina A.G., Isaev F.V., Dem'ianova M.A. Steroid myopathy. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Journal of Neurology and Psychiatry named after S.S. Korsakov). 2012; 112 (10-2): 60-4. (In Russian)
4. Chiu H.C., Chiu C.Y., Yang R.S., Chan D.C., Liu S.H., Chiang C.K. Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation. J. Cachexia Sarcopenia Muscle. 2018; 9 (3): 585-602. DOI: 10.1002/jcsm.12289.
5. Umeki D., Ohnuki Y., Mototani Y., Shiozawa K., Suita K., Fujita T., Nakamura Y., Saeki Y., Okumura S. Protective Effects of Clenbuterol against Dexamethasone-Induced Masseter Muscle Atrophy and Myosin Heavy Chain Transition. PLoS One. 2015; 10(6): e0128263. DOI: 10.1371/journal.pone.0128263.
6. Trush V.V., Sobolev V.I. Modulation by 2-adrenergic agonist formoterol of contractile dysfunction of the skeletal muscle of white rats caused by the long dexamethasone administration. Scientific Notes of V.I. Vernadsky Crimean Federal University. Biology. Chemistry. 2018; 4(4): 219-36. (In Russian)
7. Trush V.V., Sobolev V.I., Popov M.N. Evaluation of arginine efficacy in control of steroid myopathy induced by long-term dexamethasone treatment in white rats. Patologicheskaya Fiziologiya i Eksperimental`naya terapiya. (Pathological Physiology and Experimental Therapy, Russian Journal). 2018; 62 (4): 120-9. DOI: https://doi.org/10.25557/0031-2991.2018.04.120–129. (in Russian)
8. Trush V.V., Sobolev V.I. The modulatory effect of adrenaline on development of steroid myopathy induced by chronic administration of hydrocortisone in white rats. Patologicheskaya Fiziologiya i Eksperimental`naya terapiya. (Pathological Physiology and Experimental Therapy, Russian Journal). 2017; 61 (4): 104-11. DOI: 10.25557/IGPP.2017.4.8530. (in Russian)
9. Trush V.V., Sobolev V.I. The modulation by taurine of the steroid myopathy at white rats induced by long application of dexamethasone. Crimea journal of experimental and clinical medicine. 2017; 7 (2): 108-18. (in Russian)
10. Trush V.V., Sobolev V.I. Efficacy of the β2-adrenergic agonist formoterol in compensation of electrophysiological manifestations of steroid myopathy in animal experiments. Patologicheskaya Fiziologiya i Eksperimental`naya terapiya. (Pathological Physiology and Experimental Therapy, Russian Journal). 2019; 63 (3): 35-47. DOI: 10.25557/0031-2991.2019.03.35-47 (in Russian)
11. Hermann R., Mungo J., Cnota P.J., Ziegler D. Enantiomerselective pharmacokinetics, oral bioavailability, and sex effects of various alpha-lipoic acid dosage forms. Clin. Pharmacol. 2014; 6: 195-204. DOI: https://doi.org/10.2147/CPAA.S71574.
12. Luk’yanchuk V.D., Shpulina O.A. Pharmacological correction of homeostatic energy exchange under conditions of inflammatory-dystrophic process in parodontium. Eksperimental'naya i klinicheskaya farmakologiya (Experimental and clinical pharmacology). 2006; 69 (4): 51-6. (in Russian)
13. Romantsova T.I., Kuznetsov I.S. Potential opportunities for treatment of metabolic syndrome withalpha-lipoic acid (Berlithion®300). Obesity and metabolism. 2009; 3: 10-4. DOI: https://doi.org/10.14341/2071-8713-5240. (in Russian)
14. Volchegorskiĭ I.A., Rassokhina L.M., Miroshnichenko I.Iu. Insulin-potentiating action of antioxidants in experimental diabetes mellitus. Problems of Endocrinology. 2010; 56 (2): 27-35. DOI: https://doi.org/10.14341/probl201056227-35. (in Russian)
15. Kanabus M., Heales S.J., Rahman S. Development of pharmacological strategies for mitochondrial disorders. British Journal of Pharmacology. 2014; 171 (8): 1798-1817. DOI: https://doi.org/10.1111/bph.12456.
16. Jing Y., Cai X., Xu Y., Zhu C., Wang L., Wang S., Zhu X., Gao P., Zhang Y., Jiang Q., Shu G. α-Lipoic Acids Promote the Protein Synthesis of C2C12 Myotubes by the TLR2/PI3K Signaling Pathway. J. Agric. Food Chem. 2016; 64 (8): 1720-9. DOI: 10.1021/acs.jafc.5b05952.
17. Rousseau A.S., Sibille B., Murdaca J., Mothe-Satney I., Grimaldi P.A., Neels J.G. α-Lipoic acid up-regulates expression of peroxisome proliferator-activated receptor β in skeletal muscle: involvement of the JNK signaling pathway. FASEB J. 2016; 30 (3): 1287-99. DOI: 10.1096/fj.15-280453.
18. Henriksen E.J. Exercise training and the antioxidant alpha-lipoic acid in the treatment of insulin resistance and type 2 diabetes. Free Radic. Biol. Med. 2006; 40 (1): 3-12. DOI: https://doi.org/10.1016/j.freeradbiomed.2005.04.002.
19. Bilska A., Wlodec L. Lipoic acid – the drug of the future? Pharmacol. Rep. 2005; 57: 570-7.
20. Nicolson G.L. Mitochondrial dysfunction and chronic disease: treatment with natural supplements. Altern. Ther. Health Med. 2014; 20 (Suppl 1): 18-25.
21. Liu J., Peng Y., Feng Z., Shi W., Qu L., Li Y., Liu J., Long J. Reloading functionally ameliorates disuse-induced muscle atrophy by reversing mitochondrial dysfunction, and similar benefits are gained by administering a combination of mitochondrial nutrients. Free Radic. Biol. Med. 2014; 69 (Apr.): 116-28. DOI: 10.1016/j.freeradbiomed.2014.01.003.
22. Aydin A., Yildirim A.M. Effects of alpha lipoic acid on ischemia-reperfusion injury in rat hindlimb ischemia model. Ulus. Travma Acil. Cerrahi. Derg. 2016; 22 (6): 509-15. DOI: 10.5505/tjtes.2016.00258.
23. Hong O.K., Son J.W., Kwon H.S., Lee S.S., Kim S.R., Yoo S.J. Alpha-lipoic acid preserves skeletal muscle mass in type 2 diabetic OLETF rats. Nutr. Metab. (Lond). 2018; 15 (29 Sep): 66-78. DOI: 10.1186/s12986-018-0302-y.
24. Kryl'skiy E.D., Popova T.N., Safonova O.A., Kirilova E.M. Effect of lipoic acid on the activity of caspases and the characteristics of the immune and antioxidant statuses in rats with rheumatoid arthritis. Russian Journal of Bioorganic Chemistry. 2016; 42 (4): 389-96. DOI: https://doi.org/10.1134/s1068162016040130. (in Russian)
25. Yashchenko A.J., Lysenko O.N., Djowtyak B.N., Maydanyuk E.N., Kais Nairat. The influence of alpha-lipoid acid on functional state of cardiorespiratory system and physical workability in elite athletes. Fizicheskoe vospitanie studentov tvorcheskih special'nostej (Physical education of students of creative specialties). 2003; 6: 95-104. (in Russian)
26. Sun M., Qian F., Shen W., Tian C., Hao J., Sun L., Liu J. Mitochondrial nutrients stimulate performance and mitochondrial biogenesis in exhaustively exercised rats. Scand. J. Med. Sci. Sports. 2012; 22 (6): 764-75. DOI: 10.1111/j.1600-0838.2011.01314.x.
27. Tamilselvan J., Jayaraman G., Sivarajan K., Panneerselvam C. Age-dependent upregulation of p53 and cytochrome c release and susceptibility to apoptosis in skeletal muscle fiber of aged rats: role of carnitine and lipoic acid. Free Radic. Biol. Med. 2007; 43 (12): 1656-69. DOI: https://doi.org/10.1016/j.freeradbiomed.2007.08.028.
28. El-Senousey H.K., Chen B., Wang J.Y., Atta AM., Mohamed F.R., Nie Q.H. Effects of dietary vitamin C, vitamin E, and alpha-lipoic acid supplementation on the antioxidant defense system and immune-related gene expression in broilers exposed to oxidative stress by dexamethasone. Poult. Sci. 2018; 97 (1): 30-8. DOI: 10.3382/ps/pex298.
29. Mohammed M.A., Mahmoud M.O., Awaad A.S., Gamal G.M., Abdelfatah D. Alpha lipoic acid protects against dexamethasone-induced metabolic abnormalities via APPL1 and PGC-1 α up regulation. Steroids. 2019; 144 (Jan 24): 1-7. DOI: 10.1016/j.steroids.2019.01.004.
30. Canepari M., Agoni V., Brocca L., Ghigo E., Gnesi M., Minetto M.A., Bottinelli R. Structural and molecular adaptations to dexamethasone and unacylated ghrelin administration in skeletal muscle of the mice. J Physiol Pharmacol. 2018; 69(2). DOI: https://doi.org/10.26402/jpp.2018.2.14.
31. Sakai H., Kimura M., Tsukimura Y., Yabe S., Isa Y., Kai Y., Sato F., Kon R., Ikarashi N., Narita M., Chiba Y., Kamei J. Dexamethasone exacerbates cisplatin-induced muscle atrophy. Clin. Exp. Pharmacol. Physiol. 2019; 46 (1): 19-28. DOI: http://dx.doi.org/10.1111/1440-1681.13024.
32. Shin K., Ko Y.G., Jeong J., Kwon H. Fbxw7β is an inducing mediator of dexamethasone-induced skeletal muscle atrophy in vivo with the axis of Fbxw7β-myogenin-atrogenes. Mol. Biol. Rep. 2018; 45(4): 625-31. DOI: 10.1007/s11033-018-4185-9.
33. Schakman O., Gilson H., Thissen J.P. Mechanisms of glucocorticoid-induced myopathy. J. Endocrinology. 2008; 197: 1-10. DOI: https://doi.org/10.1677/joe-07-0606.
34. Parekh S., Anania F.A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007; 132(6): 2191–207. DOI: http://dx.doi.org/10.1053%2Fj.gastro.2007.03.055.
35. Jiao H., Zhou K., Zhao J., Wang X., Lin H. A high-caloric diet rich in soy oil alleviates oxidative damage of skeletal muscles induced by dexamethasone in chickens. Redox Rep. 2018; 23(1): 68-82. DOI: 10.1080/13510002.2017.1405494.
36. Inder W.J., Jang Ch., Obeysekere V.R., Alford F.P. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1 - implications for steroid-induced myopathy. Clin. Endocrinol. 2010; 73 (1): 126-32. DOI: https://doi.org/10.1111/j.1365-2265.2009.03683.x.
37. Rukovodstvo po provedeniyu doklinicheskih issledovanij lekarstvennyh sredstv (Guidelines for conducting preclinical studies of drugs), A.N. Mironova, N.D. Bunatyan, eds. Moscow: Minzdrav RF, ZAO «Grif i K»; 2012. (In Russian)
38. Gauthier GF. Skeletal muscle fiber types. In: Engel A.G., Banker B.Q., еds. Myology. Basic and clinical. New York, NY: McGraw-Hill; 1986: 255–283.
39. Galea V., De Bruin H., Cavasin R., McComas A.J. The number and relative size of motor unites estimated by computer. Muscle and Nerve. 1991; 14: 1123-30. DOI: https://doi.org/10.1002/mus.880141114.
40. Agafonov B.V., Kalinin A.P., Mozherenkov V.P. Muscle damage at hypercorticism. Kazanskij medicinskij zhurnal (Kazan Medical Journal). 1984; 5: 377-9. (In Russian)
41. Neretin V.Ya., Kotov S.V., Sapfirova V.A. On the Genesis of Neurological Changes in Itsenko-Cushing's Disease and Cushing's Syndrome. In: Voprosy endokrinologii: Respublikanskij sbornik nauchnyh rabot (Endocrinology issues: Republican collection of scientific papers). Moscow; 1983: 35-9. (In Russian)
42. Minetto M.A., Botter A., Lanfranco F., Baldi M., Ghigo E., Arvat E. Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects. Journal of Clinical Endocrinology and Metabolism. 2010; 95: 1663-71. DOI: https://doi.org/10.1210/jc.2009-2161.
43. Kamaliev R.R., Grishin S.N., Falou Zh.Yu., Ziganshin A.U. The effect of hydrocortisone, ATP and adenosine on rat skeletal muscle contraction. Kazan medical journal. 2009; 90 (4): 556-9. (In Russian)
44. Jurisic-Erzen D., Starcevic-Klasan G., Ivanac D., Peharec S., Girotto D., Jerkovic R. The effects of alpha-lipoic acid on diabetic myopathy. J. Endocrinol. Invest. 2018; 41 (2): 203-9. DOI: 10.1007/s40618-017-0720-0.
45. Vishwanath S., Abdullah M., Elbalkhi A., Ambrus J.L.Jr. Metabolic myopathy presenting with polyarteritis nodosa: a case report. J. Med. Case Rep. 2011; 5 (Jun 30): 262-4. DOI: 10.1186/1752-1947-5-262.
46. Tregubova I.A., Kosolapova V.A., Spasov A.A. Antioxidants: Current Situation and Perspectives. Uspekhi fiziologicheskih nauk (Advances in physiological sciences). 2012; 43 (1): 75-94. (In Russian)
47. Chae C.H., Shin C.H., Kim H.T. The combination of alpha-lipoic acid supplementation and aerobic exercise inhibits lipid peroxidation in rat skeletal muscles. Nutr. Res. 2008; 28 (6): 399-405. DOI: 10.1016/j.nutres.2008.02.010.
48. Kinnunen S., Oksala N., Hyyppä S., Sen C.K., Radak Z., Laaksonen D.E., Szabó B., Jakus J., Atalay M. alpha-Lipoic acid modulates thiol antioxidant defenses and attenuates exercise-induced oxidative stress in standardbred trotters. Free Radic. Res. 2009; 43 (8): 697-705. DOI: 10.1080/10715760903037673.
49. Favero G., Rodella L.F., Nardo L., Giugno L., Cocchi M.A., Borsani E., Reiter R.J., Rezzani R. A comparison of melatonin and α-lipoic acid in the induction of antioxidant defences in L6 rat skeletal muscle cells. Age (Dordr). 2015; 37 (4): 9824. DOI: 10.1007/s11357-015-9824-7.
50. Rossman M.J., Groot H.J., Reese V., Zhao J., Amann M., Richardson R.S. Oxidative stress and COPD: the effect of oral antioxidants on skeletal muscle fatigue. Med. Sci. Sports Exerc. 2013; 45 (7): 1235-43. DOI: 10.1249/MSS.0b013e3182846d7e.
51. Wray D.W., Nishiyama S.K., Monnet A., Wary C., Duteil S.S., Carlier P.G., Richardson R.S. Antioxidants and aging: NMR-based evidence of improved skeletal muscle perfusion and energetics. Am. J. Physiol. Heart Circ. Physiol. 2009; 297 (5): H1870-5. DOI: 10.1152/ajpheart.00709.2009.
